Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Free Cash Flow (2018 - 2025)

Inmune Bio's Free Cash Flow history spans 8 years, with the latest figure at -$5.6 million for Q3 2025.

  • For Q3 2025, Free Cash Flow rose 19.38% year-over-year to -$5.6 million; the TTM value through Sep 2025 reached -$30.8 million, down 19.79%, while the annual FY2024 figure was -$33.4 million, 178.47% down from the prior year.
  • Free Cash Flow for Q3 2025 was -$5.6 million at Inmune Bio, up from -$7.4 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$1.1 million in Q1 2023 and bottomed at -$11.0 million in Q4 2024.
  • The 5-year median for Free Cash Flow is -$5.7 million (2021), against an average of -$6.1 million.
  • The largest annual shift saw Free Cash Flow surged 87.13% in 2023 before it plummeted 555.21% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at -$9.8 million in 2021, then skyrocketed by 41.77% to -$5.7 million in 2022, then surged by 40.28% to -$3.4 million in 2023, then tumbled by 223.82% to -$11.0 million in 2024, then soared by 48.86% to -$5.6 million in 2025.
  • Per Business Quant, the three most recent readings for INMB's Free Cash Flow are -$5.6 million (Q3 2025), -$7.4 million (Q2 2025), and -$6.8 million (Q1 2025).